The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1910-1918

  Camerin, Monica ^a   Magaraggia, Michela ^a   Soncin, Marina ^a   Jori, Giulio ^a   Moreno, Miguel ^b   Chambrier, Isabelle ^b   Cook, Michael J ^b   Russell, David A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Melanoma; Nanoparticles; Pharmacokinetics; Photodynamic therapy; Photosensitisation; Phthalocyanines; Singlet oxygen

Indexed keywords

1,1',4,4',8,8',15,15',18,18',22,22' TETRADECAKISDECYL 25,25' (11,11' DITHIODIUNDECYL)DIPHTHALOCYANINE; CREMOPHOR; GOLD NANOPARTICLE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; METAL NANOPARTICLE; ORGANOMETALLIC COMPOUND; ZN(II)-PHTHALOCYANINE;

AMELANOTIC MELANOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CANCER TISSUE; CAPILLARY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; IN VIVO STUDY; IRRADIATION; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVE EPILEPSY; PRIORITY JOURNAL; SKIN; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; FEMALE; MELANOMA, AMELANOTIC; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN NEOPLASMS;

ANIMALS; FEMALE; INDOLES; MELANOMA, AMELANOTIC; METAL NANOPARTICLES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS;

EID: 77953286154     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.037     Document Type: Article

References (52)

1. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 90 (1998) 889-905
2. Triesscheijn M., Baas P., Schellensa J.H.M., and Stewarta F.A. Photodynamic therapy in oncology. The Oncologist 11 (2000) 1034-1044
3. Juzeniene A., Peng Q., and Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci 6 (2007) 1234-1245
4. O'Connor A.E., Gallagher W.M., and Byrne A.T. Porphyrin and Nonporphyrin photosensitisers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 85 (2009) 1053-1074
5. Boyle R.W., and Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol 64 (1996) 469-485
6. Cinteza L.O., Ohulchanskyy T.J., Sahoo Y., et al. Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. Mol Pharm 3 (2006) 415-423
7. Roy I., Ohulchanskyy T.J., Pudavar H.E., et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitising anticancer drugs: novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125 (2003) 7860-7865
8. Chatterjee D.K., Fong L.S., and Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev 60 (2008) 1627-1637
9. Bechet D., Couleaud P., Frochot C., Viriot M.L., and Barberi-Heyob M. Nanoparticles for photodynamic therapy agent delivery. Trends Biotechnol 26 (2008) 612-621
10. 3 incorporated in polyacrylamide PEBBLES. Sens Actuators B-Chem 90 (2003) 82-89
11. Wang S.Z., Gao R.M., Zhou F.M., and Selke M. Nanomaterials and singlet oxygen photosensitisers: potential applications in photodynamic therapy. J Mater Chem 14 (2004) 487-493
12. Gao D., Agayan R.R., Xu H., Philbert M.A., and Kopelman R. Nanoparticles for two-photon photodynamic therapy in living cells. Nano Lett 6 (2006) 2383-2386
13. Moghimi S.M., Hunter A.C., and Murray J.C. Nanomedicine: current status and future prospects. FASEB J 19 (2005) 311-330
14. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56 (2004) 1649-1659
15. Konan Y.N., Berton M., Gurny R., and Allemann E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm Sci 18 (2003) 241-249
16. McCarthy J.R., Perez J.M., Bruckner C., and Weissleder R. Polymeric nanoparticle preparation that eradicates tumors. Nano Lett 5 (2005) 2552-2556
17. Gomes A.J., Lunardi L.O., Marchetti J.M., Lunardi C.N., and Tedesco A.C. Photobiological and ultrastructural studies of nanoparticles of poly(lactic-co-glycolic acid)-containing bacteriochlorophyll-a as a photosensitizer useful for PDT treatment. Drug Deliv 12 (2005) 159-164
18. Konan-Kouakou Y.N., Boch R., Gurny R., and Allemann E. In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Control Release 103 (2005) 83-91
19. Tang W., Xu H., Kopelman R., and Philbert M.A. Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol 81 (2005) 242-249
20. Zeisser-Labouebe M., Lange N., Gurny R., and Delie F. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm 326 (2006) 174-181
21. Ricci Jr. E., and Marchetti J.M. Preparation, characterization, photocytotoxicity assay of PLGA nanoparticles containing zinc(II) phthalocyanine for photodynamic therapy use. J Microencapsul 23 (2006) 523-538
22. Ricci Jr. E., and Marchetti J.M. Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. Int J Pharm 310 (2006) 187-195
23. Allemann E., Brasseur N., Benrezzak O., et al. PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro-zinc-phthalocyanine to EMT-6 mouse mammary-tumors. J Pharm Pharmacol 47 (1995) 382-387
24. Yan F., and Kopelman R. The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem Photobiol 78 (2003) 587-591
25. Davydenko M.O., Radchenko E.O., Yaschchuk V.M., et al. Sensibilization of fullerene C-60 immobilized at silica nanoparticles for cancer photodynamic therapy. J Mol Liq 127 (2006) 145-147
26. Mazzaglia A., Angelini N., Darcy R., et al. Novel heterotopic colloids of anionic porphyrins entangled in cationic amphiphilic cyclodextrins: spectroscopy investigation and intracellular delivery. Chem Eur J 9 (2003) 5762-5769
27. Sortino S., Mazzaglia A., Monsù Scolaro L., et al. Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as a "carrier-sensitizer" system in photodynamic cancer therapy. Biomaterials 27 (2006) 4256-4265
28. Hone D.C., Walker P.I., Evans-Gowing R., et al. Generation of cytotoxic singlet oxygen via phthalocyanine-stabilized gold nanoparticles: a potential delivery vehicle for photodynamic therapy. Langmuir 18 (2002) 2985-2987
29. Wieder M.E., Hone D.C., Cook M.J., Handsley M.M., Gavrilovic J., and Russell D.A. Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a 'Trojan horse'. Photochem Photobiol Sci 5 (2006) 727-734
30. Cheng Y., Samia A.C., Meyers J.D., et al. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 130 (2008) 10643-10647
31. Reddy G.R., Bhojani M.S., McConville P., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 12 (2006) 6677-6686
32. Sun Y., Chen Z.L., Yang X.X., et al. Magnetic chitosan nanoparticles as a drug delivery system for targeting photodynamic therapy. Nanotechnology 20 (2009) AR 135102
33. Hu Z.Y., Pan Y.F., Wang J.W., et al. Meso-tetra (carboxyphenyl) porphyrin (TCPP) nanoparticles were internalized by SW480 cells by a clathrin-mediated endocytosis pathway to induce high photocytotoxicity. Biomed Pharmacother 63 (2009) 155-164
34. Nishiyama N., Nakagishi Y., Morimoto Y., et al. Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine. J Control Release 133 (2009) 245-251
35. Zhang M., Murakami T., Ajima K., et al. Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy. Proc Natl Acad Sci 105 (2008) 14773-14778
36. Taub A.F. Photodynamic therapy in dermatology. In: Hamblin M.R., and Mroz P. (Eds). Advances in photodynamic therapy: basic, translational and clinical (2008), Artech House, Boston 419-442
37. Soncin M., Busetti A., Reddi E., et al. Pharmacokinetic and phototherapeutic properties of axially substituted Si(IV)-tetradibenzobarreleno-octabutoxyphthalocyanines. J Photochem Photobiol B: Biol 40 (1997) 163-167
38. Fabris C., Vicente M.G.H., Hao E., et al. Tumour-localizing and -photosensitising properties of meso-tetra(4-nido-carboranylphenyl)porphyrin. J Photochem Photobiol B: Biol 89 (2007) 131-136
39. Reddi E., Zhou C., Biolo R., Menegaldo E., and Jori G. Liposome or LDL-administered Zn(II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency. Br J Cancer 61 (1990) 407-411
40. Ometto C., Fabris C., Milanesi C., Jori G., Cook M.J., and Russell D.A. Tumour-localising and -photosensitising properties of a novel zinc(II) octadecylphthalocyanine. Br J Cancer 74 (1996) 1891-1899
41. Fabris C., Ometto C., Milanesi C., et al. Tumour-localizing and tumour-photosensitizing properties of zinc(II)-octapentylphthalocyanine. J Photochem Photobiol B: Biol 39 (1997) 279-284
42. Jori G. Photodynamic therapy: basic and preclinical aspects. In: Horspool W., and Lenci F. (Eds). Organic photochemistry and photobiology (2004), CRC Press, Boca Raton, FL 146-1-146-10
43. Jori G. Tumour photosensitisers: approaches to enhance the selectivity and efficiency of photodynamic therapy. J Photochem Photobiol B: Biol 36 (1996) 87-93
44. Friedberg J.S., Mick R., and Stevenson J. A phase I study of Foscan-mediated photodynamic therapy in patients with mesothelioma. Ann Thorac Surg 75 (2003) 952-959
45. Castano A.P., Demidova T.N., and Hamblin M.R. Mechanisms in photodynamic therapy. 2. Cellular signalling, cell metabolism and modes of cell death. Photodiag Photodyn Ther 2 (2005) 1-23
46. Duncan R., and Sat Y.N. Tumour targeting by enhanced permeability and retention effect. Ann Oncol 9 (1998) 39-52
47. Paciotti G.F., Kingston D.G.I., and Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumour-targeted drug delivery vectors. Drug Deliv Res 67 (2006) 47-53
48. Sharman W.M., van Lier J.E., and Allen C.M. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 56 (2004) 53-76
49. Nimjee S.M., Rusconi C.P., and Sullenger B.A. Aptamers: an emerging class of therapeutics. Ann Rev Med 72 (2005) 250-256
50. Hou L.C., Veeravagu A., and Hsu A.R. Recurrent gliobastoma multiforme: a review of natural history and management options. Neurosurg Focus 20 (2006) 5-11
51. Carstensen H., Muller R.H., and Muller P.W. Particle-size, surface hydrophobicity and interaction with serum of fat emulsions and model drug carriers as parameters related to RES uptake. Clin Nutr 11 (1992) 289-297
52. Gbadamosi J.K., Hunter A.C., and Moghimi S.M. Pegylation of microspheres generates a heterogeneous population of particles with different surface characteristics and biological performance. FEBS Lett 532 (2002) 338-344